Company Ticker News October 15, 2021Merck (MRK) Stock Sinks As Market Gains: What You Should Know 0 0 Share
Press Release October 14, 2021FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1) 0 0 Share
Company Ticker News October 14, 2021Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company 0 0 Share
Company Ticker News October 14, 2021Holocene Advisors says Merck's offer undervalues Acceleron 0 0 Share
Company Ticker News October 13, 2021Merck's Covid-19 Antiviral Can Still Get FDA Authorization, Despite Safety Concerns, Analyst Says 0 0 Share
Company Ticker News October 12, 2021Dr. Scott Gottlieb says Merck's Covid pill ‘can make a real difference' 0 0 Share
